Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EB-DTKN-401 in Advanced Melanoma
NCT07627698Phase 2Recruiting
- Sponsor
- Biotech Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of EB-DTKN-401 in cutaneous melanoma (CM), Uveal melanoma (UM), sponsored by Biotech Pharmaceutical. Started Mar 2026; status: recruiting.
02
Drugs
EB-DTKN-401
03
Conditions
cutaneous melanoma (CM)Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT07627698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07627698.